BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24654465)

  • 1. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute toxicity of postoperative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy.
    Marjanovic D; Plesinac Karapandzic V; Stojanovic Rundic S; Tomasevic A; Saric M; Miskovic I; Nidzovic B; Petrasinovic P
    J BUON; 2019; 24(6):2347-2354. PubMed ID: 31983105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
    Wan J; Liu K; Li K; Li G; Zhang Z
    Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of survival, acute toxicities, and dose-volume parameters between intensity-modulated radiotherapy with or without internal target volume delineation method and three-dimensional conformal radiotherapy in cervical cancer patients: A retrospective and propensity score-matched analysis.
    Liang YQ; Feng SQ; Xie WJ; Jiang QZ; Yang YF; Luo R; Kidd EA; Zhai TT; Xie LX
    Cancer Med; 2022 Jan; 11(1):151-165. PubMed ID: 34821082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
    Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
    Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
    Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
    Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
    Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
    Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
    Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective dosimetric and clinical comparison of acute hematological toxicities in three-dimensional conformal radiation therapy and intensity modulated radiation therapy with concurrent chemotherapy in carcinoma cervix.
    Avinash HU; Arul Ponni TR; Janaki MG; Kirthi Koushik AS; Kumar SM
    J Cancer Res Ther; 2015; 11(1):83-7. PubMed ID: 25879342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters.
    Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Tamari K; Yamashita M; Unno H; Kinose Y; Kozasa K; Sumida I; Otani Y; Kimura T; Ogawa K
    Radiat Oncol; 2015 Aug; 10():180. PubMed ID: 26300325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Aydogan B; Liang Y; Yeginer M; Hasselle MD; Dandekar V; Bafana R; Yashar CM; Mundt AJ; Roeske JC; Mell LK
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):800-7. PubMed ID: 20400238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
    Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
    Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
    Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
    Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study for dosimetric assessment and clinical impact of bone marrow sparing intensity-modulated radiation therapy versus 3-dimensional conformal radiation therapy on hematological and gastrointestinal toxicities in cervical cancer.
    Kapoor AR; Bhalavat RL; Chandra M; Pareek V; Moosa Z; Markana S; Nandakumar P; Bauskar P; Shincy NV
    J Cancer Res Ther; 2022; 18(6):1490-1497. PubMed ID: 36412399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
    Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.